SanaCurrents assigns an advantageous probability PDS Biotechnology and its partner, the MD Anderson Cancer Center, will report positive data later this year from their cervical cancer trial, which combines PDS0101 and chemoradiation therapy.
Welcome to The GeoWire As we enter the next week and in case you missed it, we wanted to reiterate the Call To Action that was put out on a technology stock that was originally in our FundiTrading Model Portfolio. […]
This content is for members only
When SanaCurrents issued its report on October 30, 2020, Annexon’s stock closed at $20.81 per share. The stock reached a high of $33.89 per share in March 2021 before leveling to a $20 to $22 per share range between May and mid-October. Annexon began to feel the biotech pull back in the latter months of last year, dropping to slightly more than $10 per share.
We’ll be getting back to the normal GeoWire format next month, but we wanted to take this first edition of the new year to look back at everything we were up to in 2021, and to offer you a new special rate to enjoy our new high conviction stock idea that is seeing massive insider buying, while the market is ignoring a situation we view as a post Christmas gift. It’s our top multibagger idea heading into 2022!
Happy New Year! With another year down the drain, we looked back at some of the things that we embarked upon in 2021, as well as some of the recurring subject matter that we tracked during each passing month. It’s likely that a good deal of coverage is going to bleed into 2022, but our pipeline of new stock ideas is always robust and on the immediate horizon,
- 1
- 2